These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24644095)

  • 1. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
    Kakuda TN; Opsomer M; Timmers M; Iterbeke K; Van De Casteele T; Hillewaert V; Petrovic R; Hoetelmans RM
    J Clin Pharmacol; 2014 Aug; 54(8):949-57. PubMed ID: 24644095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers.
    Kakuda TN; Van De Casteele T; Petrovic R; Neujens M; Salih H; Opsomer M; Hoetelmans RM
    Antivir Ther; 2014; 19(6):597-606. PubMed ID: 24964392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
    Sekar VJ; Spinosa-Guzman S; De Paepe E; De Pauw M; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2008 Jan; 48(1):60-5. PubMed ID: 18094220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
    Sekar V; Kestens D; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2007 Apr; 47(4):479-84. PubMed ID: 17389557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
    Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
    Sevinsky H; Tao X; Wang R; Ravindran P; Sims K; Xu X; Jariwala N; Bertz R
    Antivir Ther; 2015; 20(5):493-500. PubMed ID: 25361436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.
    Kakuda TN; Sekar V; Lavreys L; De Paepe E; Stevens T; Vanstockem M; Vangeneugden T; Hoetelmans RM
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):346-52. PubMed ID: 27129006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
    Sekar VJ; Lefebvre E; Mariën K; De Pauw M; Vangeneugden T; Hoetelmans RM
    Ther Drug Monit; 2007 Dec; 29(6):795-801. PubMed ID: 18043478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
    Samineni D; Desai PB; Sallans L; Fichtenbaum CJ
    J Clin Pharmacol; 2012 Jun; 52(6):922-31. PubMed ID: 21712498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
    Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
    Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
    Sekar VJ; Lefebvre E; Guzman SS; Felicione E; De Pauw M; Vangeneugden T; Hoetelmans RM
    Antivir Ther; 2008; 13(4):563-9. PubMed ID: 18672535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.
    Renjifo B; van Wyk J; Salem AH; Bow D; Ng J; Norton M
    AIDS Rev; 2015; 17(1):37-46. PubMed ID: 25586481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.